Shopping Cart 0
Cart Subtotal
AED 0

Cotinga Pharmaceuticals Inc (COT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Cotinga Pharmaceuticals Inc (Cotinga), formerly Critical Outcome Technologies Inc, is a developer of targeted therapeutics with focus on oncology. The company offers pipeline products such as COTI-2 targeting p53 and COTI-259 targeting KRAS. Its research includes program, indication, screening, lead identification, preclinical, among others. Cotinga's COTI-2 is a novel small molecule activator of misfolded mutant p53 proteins for the treatment of ovarian and other gynecological cancers. It also offers treatment for small cell lung cancer and other products for Alzheimer's disease, HIV integrase inhibitors, and multiple sclerosis. The company uses its proprietary technology Chemsas, a multistage computational platform technology based on hybrid of machine learning technologies and proprietary algorithms which allows accurate prediction of biological activity from the molecular structure. It serves pharmaceutical and biotechnology companies. Cotinga is headquartered in Boston, Massachusetts, the US.

Cotinga Pharmaceuticals Inc (COT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Critical Outcome Technologies And Portage Biotech To Form Joint Venture 12

Critical Outcome Technologies Enters Into Drug Discovery Agreement With Global Pharma Company 14

Critical Outcome Technologies Enters Into Agreement With Delmar Chemicals To Develop New Drug Candidates 15

Critical Outcome Technologies Enters Into Collaboration Agreement With University of Western Ontario 16

Equity Offering 17

Cotinga Pharma Raises USD1.6 Million in Private Placement of Shares and Warrants 17

Critical Outcome Technologies Raises USD0.4 Million in Second Tranche of Private Placement of Units 18

Critical Outcome Technologies Raises USD1.2 Million in First Tranche of Private Placement of Units 19

Critical Outcome Technologies Raises USD1.2 Million in Private Placement of Shares upon Exercise of Warrants 20

Critical Outcome Technologies Raises USD1 Million in Private Placement of Shares upon Exercise of Warrants 21

Critical Outcome Technologies Raises USD1 Million in Private Placement of Units 22

Critical Outcome Technologies Raises USD1 Million in Private Placement of Shares Upon Exercise of Warrants 23

Critical Outcome Raises USD0.6 Million in Second Tranche of Private Placement of Shares 24

Critical Outcome Raises USD0.36 Million in First Tranche of Private Placement of Shares 25

Critical Outcome Raises USD0.4 Million in Private Placement of Units 26

Critical Outcome Raises USD0.22 Million in Private Placement of Units 27

Critical Outcome Technologies Raises USD0.6 Million in Third Tranche of Private Placement of Units 28

Critical Outcome Technologies Completes Private Placement Of Units For USD 0.1 Million 30

Critical Outcome Technologies Completes Third Tranche Of Private Placement Of Units For USD 0.12 Million 31

Critical Outcome Technologies Completes Second Tranche of Private Placement of Units for USD0.2 Million 33

Critical Outcome Technologies Completes Private Placement Of Units For USD 0.5 Million 34

Critical Outcome Technologies Completes Final Tranche Of Private Placement Of Units For USD 0.3 Million 35

Debt Offering 36

Critical Outcome Technologies Completes Private Placement Of Debentures For USD 0.4 Million 36

Cotinga Pharmaceuticals Inc-Key Competitors 38

Cotinga Pharmaceuticals Inc-Key Employees 39

Cotinga Pharmaceuticals Inc-Locations And Subsidiaries 40

Head Office 40

Other Locations & Subsidiaries 40

Recent Developments 41

Financial Announcements 41

Oct 02, 2018: Cotinga Pharmaceuticals reports fiscal 2019 first quarter financial and operating results 41

Aug 29, 2018: Cotinga Pharmaceuticals reports fiscal 2018 fourth quarter and full year financial and operating results 43

Apr 03, 2018: Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results 45

Dec 29, 2017: Critical Outcome Technologies Reports Fiscal 2018 Second Quarter Financial and Operating Results 47

Sep 29, 2017: Critical Outcome Technologies Reports Fiscal 2018 First Quarter Financial and Operating Results 49

Aug 28, 2017: Critical Outcome Technologies Announces Fourth Quarter and Full Year 2017 Financial Results 51

Mar 16, 2017: Critical Outcome Technologies Reports Third Quarter Financial and Operating Results for Fiscal Year 2017 53

Corporate Communications 54

Jul 02, 2018: Cotinga Pharmaceuticals announces management and board changes 54

May 11, 2017: Critical Outcome Technologies Appoints Experienced Biotech Leader as Chief Scientific Officer 55

Feb 01, 2017: Critical Outcome Technologies Announces Departure of Chief Scientific Officer 56

Other Significant Developments 57

Jan 08, 2018: Critical Outcome Technologies Changes Name to Cotinga Pharmaceuticals 57

Dec 21, 2017: Critical Outcome Technologies Provides Scientific and Business Update at Annual General Meeting and Announces Approval of Name Change 58

Appendix 59

Methodology 59

About GlobalData 59

Contact Us 59

Disclaimer 59


List Of Figure

List of Figures

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cotinga Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Critical Outcome Technologies And Portage Biotech To Form Joint Venture 12

Critical Outcome Technologies Enters Into Drug Discovery Agreement With Global Pharma Company 14

Critical Outcome Technologies Enters Into Agreement With Delmar Chemicals To Develop New Drug Candidates 15

Critical Outcome Technologies Enters Into Collaboration Agreement With University of Western Ontario 16

Cotinga Pharma Raises USD1.6 Million in Private Placement of Shares and Warrants 17

Critical Outcome Technologies Raises USD0.4 Million in Second Tranche of Private Placement of Units 18

Critical Outcome Technologies Raises USD1.2 Million in First Tranche of Private Placement of Units 19

Critical Outcome Technologies Raises USD1.2 Million in Private Placement of Shares upon Exercise of Warrants 20

Critical Outcome Technologies Raises USD1 Million in Private Placement of Shares upon Exercise of Warrants 21

Critical Outcome Technologies Raises USD1 Million in Private Placement of Units 22

Critical Outcome Technologies Raises USD1 Million in Private Placement of Shares Upon Exercise of Warrants 23

Critical Outcome Raises USD0.6 Million in Second Tranche of Private Placement of Shares 24

Critical Outcome Raises USD0.36 Million in First Tranche of Private Placement of Shares 25

Critical Outcome Raises USD0.4 Million in Private Placement of Units 26

Critical Outcome Raises USD0.22 Million in Private Placement of Units 27

Critical Outcome Technologies Raises USD0.6 Million in Third Tranche of Private Placement of Units 28

Critical Outcome Technologies Completes Private Placement Of Units For USD 0.1 Million 30

Critical Outcome Technologies Completes Third Tranche Of Private Placement Of Units For USD 0.12 Million 31

Critical Outcome Technologies Completes Second Tranche of Private Placement of Units for USD0.2 Million 33

Critical Outcome Technologies Completes Private Placement Of Units For USD 0.5 Million 34

Critical Outcome Technologies Completes Final Tranche Of Private Placement Of Units For USD 0.3 Million 35

Critical Outcome Technologies Completes Private Placement Of Debentures For USD 0.4 Million 36

Cotinga Pharmaceuticals Inc, Key Competitors 38

Cotinga Pharmaceuticals Inc, Key Employees 39

Cotinga Pharmaceuticals Inc, Other Locations 40

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Cotinga Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Cotinga Pharmaceuticals Inc (Cotinga), formerly Critical Outcome Technologies Inc, is a developer of targeted therapeutics with focus on oncology. The company offers pipeline products such as COTI-2 targeting p53 and COTI-259 targeting KRAS. Its research includes program, indication, screening, lead identification, preclinical, among others. Cotinga's COTI-2 is a novel small molecule activator of misfolded mutant p53 proteins for the treatment of ovarian and other gynecological cancers. It also offers treatment for small cell lung cancer and other products for Alzheimer's disease, HIV integrase inhibitors, and multiple sclerosis. The company uses its proprietary technology Chemsas, a multistage computational platform technology based on hybrid of machine learning technologies and proprietary algorithms which allows accurate prediction of biological activity from the molecular structure. It serves pharmaceutical and biotechnology companies. Cotinga is headquartered in Boston, Massachusetts, the US.

Cotinga Pharmaceuticals Inc (COT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Critical Outcome Technologies And Portage Biotech To Form Joint Venture 12

Critical Outcome Technologies Enters Into Drug Discovery Agreement With Global Pharma Company 14

Critical Outcome Technologies Enters Into Agreement With Delmar Chemicals To Develop New Drug Candidates 15

Critical Outcome Technologies Enters Into Collaboration Agreement With University of Western Ontario 16

Equity Offering 17

Cotinga Pharma Raises USD1.6 Million in Private Placement of Shares and Warrants 17

Critical Outcome Technologies Raises USD0.4 Million in Second Tranche of Private Placement of Units 18

Critical Outcome Technologies Raises USD1.2 Million in First Tranche of Private Placement of Units 19

Critical Outcome Technologies Raises USD1.2 Million in Private Placement of Shares upon Exercise of Warrants 20

Critical Outcome Technologies Raises USD1 Million in Private Placement of Shares upon Exercise of Warrants 21

Critical Outcome Technologies Raises USD1 Million in Private Placement of Units 22

Critical Outcome Technologies Raises USD1 Million in Private Placement of Shares Upon Exercise of Warrants 23

Critical Outcome Raises USD0.6 Million in Second Tranche of Private Placement of Shares 24

Critical Outcome Raises USD0.36 Million in First Tranche of Private Placement of Shares 25

Critical Outcome Raises USD0.4 Million in Private Placement of Units 26

Critical Outcome Raises USD0.22 Million in Private Placement of Units 27

Critical Outcome Technologies Raises USD0.6 Million in Third Tranche of Private Placement of Units 28

Critical Outcome Technologies Completes Private Placement Of Units For USD 0.1 Million 30

Critical Outcome Technologies Completes Third Tranche Of Private Placement Of Units For USD 0.12 Million 31

Critical Outcome Technologies Completes Second Tranche of Private Placement of Units for USD0.2 Million 33

Critical Outcome Technologies Completes Private Placement Of Units For USD 0.5 Million 34

Critical Outcome Technologies Completes Final Tranche Of Private Placement Of Units For USD 0.3 Million 35

Debt Offering 36

Critical Outcome Technologies Completes Private Placement Of Debentures For USD 0.4 Million 36

Cotinga Pharmaceuticals Inc-Key Competitors 38

Cotinga Pharmaceuticals Inc-Key Employees 39

Cotinga Pharmaceuticals Inc-Locations And Subsidiaries 40

Head Office 40

Other Locations & Subsidiaries 40

Recent Developments 41

Financial Announcements 41

Oct 02, 2018: Cotinga Pharmaceuticals reports fiscal 2019 first quarter financial and operating results 41

Aug 29, 2018: Cotinga Pharmaceuticals reports fiscal 2018 fourth quarter and full year financial and operating results 43

Apr 03, 2018: Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results 45

Dec 29, 2017: Critical Outcome Technologies Reports Fiscal 2018 Second Quarter Financial and Operating Results 47

Sep 29, 2017: Critical Outcome Technologies Reports Fiscal 2018 First Quarter Financial and Operating Results 49

Aug 28, 2017: Critical Outcome Technologies Announces Fourth Quarter and Full Year 2017 Financial Results 51

Mar 16, 2017: Critical Outcome Technologies Reports Third Quarter Financial and Operating Results for Fiscal Year 2017 53

Corporate Communications 54

Jul 02, 2018: Cotinga Pharmaceuticals announces management and board changes 54

May 11, 2017: Critical Outcome Technologies Appoints Experienced Biotech Leader as Chief Scientific Officer 55

Feb 01, 2017: Critical Outcome Technologies Announces Departure of Chief Scientific Officer 56

Other Significant Developments 57

Jan 08, 2018: Critical Outcome Technologies Changes Name to Cotinga Pharmaceuticals 57

Dec 21, 2017: Critical Outcome Technologies Provides Scientific and Business Update at Annual General Meeting and Announces Approval of Name Change 58

Appendix 59

Methodology 59

About GlobalData 59

Contact Us 59

Disclaimer 59


List Of Figure

List of Figures

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Cotinga Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Critical Outcome Technologies And Portage Biotech To Form Joint Venture 12

Critical Outcome Technologies Enters Into Drug Discovery Agreement With Global Pharma Company 14

Critical Outcome Technologies Enters Into Agreement With Delmar Chemicals To Develop New Drug Candidates 15

Critical Outcome Technologies Enters Into Collaboration Agreement With University of Western Ontario 16

Cotinga Pharma Raises USD1.6 Million in Private Placement of Shares and Warrants 17

Critical Outcome Technologies Raises USD0.4 Million in Second Tranche of Private Placement of Units 18

Critical Outcome Technologies Raises USD1.2 Million in First Tranche of Private Placement of Units 19

Critical Outcome Technologies Raises USD1.2 Million in Private Placement of Shares upon Exercise of Warrants 20

Critical Outcome Technologies Raises USD1 Million in Private Placement of Shares upon Exercise of Warrants 21

Critical Outcome Technologies Raises USD1 Million in Private Placement of Units 22

Critical Outcome Technologies Raises USD1 Million in Private Placement of Shares Upon Exercise of Warrants 23

Critical Outcome Raises USD0.6 Million in Second Tranche of Private Placement of Shares 24

Critical Outcome Raises USD0.36 Million in First Tranche of Private Placement of Shares 25

Critical Outcome Raises USD0.4 Million in Private Placement of Units 26

Critical Outcome Raises USD0.22 Million in Private Placement of Units 27

Critical Outcome Technologies Raises USD0.6 Million in Third Tranche of Private Placement of Units 28

Critical Outcome Technologies Completes Private Placement Of Units For USD 0.1 Million 30

Critical Outcome Technologies Completes Third Tranche Of Private Placement Of Units For USD 0.12 Million 31

Critical Outcome Technologies Completes Second Tranche of Private Placement of Units for USD0.2 Million 33

Critical Outcome Technologies Completes Private Placement Of Units For USD 0.5 Million 34

Critical Outcome Technologies Completes Final Tranche Of Private Placement Of Units For USD 0.3 Million 35

Critical Outcome Technologies Completes Private Placement Of Debentures For USD 0.4 Million 36

Cotinga Pharmaceuticals Inc, Key Competitors 38

Cotinga Pharmaceuticals Inc, Key Employees 39

Cotinga Pharmaceuticals Inc, Other Locations 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Cotinga Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.